---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029666"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:29:14.222305+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma

## Summary
- Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
- Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.
- Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.
- Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.
- December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital.

## SEC filing metadata
- accession: 0001104659-25-029666
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/0001104659-25-029666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/tm2510813d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029666
- JSON: https://secwatch.observer/filing/0001104659-25-029666.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.